|
gptkbp:instanceOf
|
gptkb:drug
gptkb:acetylcholinesterase_inhibitor
|
|
gptkbp:approvedBy
|
1955
|
|
gptkbp:ATCCode
|
N07AA02
|
|
gptkbp:brand
|
Mestinon
Regonol
|
|
gptkbp:CASNumber
|
101-26-8
|
|
gptkbp:chemicalClass
|
quaternary ammonium compound
|
|
gptkbp:contraindication
|
mechanical intestinal obstruction
urinary obstruction
|
|
gptkbp:discoveredBy
|
gptkb:Mary_Walker
|
|
gptkbp:eliminationHalfLife
|
1-2 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C9H13BrN2O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pyridostigmine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:MeSH_ID
|
D011662
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
4986
DB00545
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
muscle twitching
abdominal cramps
increased salivation
|
|
gptkbp:UNII
|
0E22F3765H
|
|
gptkbp:usedFor
|
gptkb:myasthenia_gravis
prophylaxis of organophosphate poisoning
reversal of nondepolarizing neuromuscular blockade
|
|
gptkbp:bfsParent
|
gptkb:Lambert-Eaton_Myasthenic_Syndrome
gptkb:Physostigmine
|
|
gptkbp:bfsLayer
|
6
|